Tandem Diabetes Care (TNDM) Interest & Investment Income (2013 - 2025)
Tandem Diabetes Care (TNDM) posted Interest & Investment Income of $4.2 million for Q1 2025, down 7.05% on a QoQ basis from $4.5 million in Q4 2024, and down 21.1% year-over-year from $5.3 million in Q1 2024.
Tandem Diabetes Care (TNDM) Interest & Investment Income (2013 - 2025) Analysis & Trends
Tandem Diabetes Care's Interest & Investment Income history runs 13 years deep, the most recent figure standing at $4.2 million for Q1 2025.
- Quarterly Interest & Investment Income fell 21.1% year-over-year to $4.2 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $16.9 million (down 24.36% YoY) and the FY2024 annual result came in at $18.0 million, down 21.28% from the prior year.
- Interest & Investment Income was $4.2 million for Q1 2025 at Tandem Diabetes Care, down from $4.5 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $5.9 million in Q1 2023 and bottomed at -$47000.0 in Q4 2021.
- A 5-year average of $3.0 million and a median of $3.1 million in 2022 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2021 — Interest & Investment Income plunged 114.16% — and 2022, when it jumped 6687.23%.
- Tandem Diabetes Care's Interest & Investment Income stood at -$47000.0 in 2021, then soared by 6687.23% to $3.1 million in 2022, then jumped by 79.36% to $5.6 million in 2023, then declined by 18.76% to $4.5 million in 2024, then declined by 7.05% to $4.2 million in 2025.
- Business Quant data shows TNDM's Interest & Investment Income at $4.2 million in Q1 2025, $4.5 million in Q4 2024, and $5.3 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 106.00 Mn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | - |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 33.50 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | - |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | - |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 40.98 Mn |
| 10 | Tandem Diabetes Care | 1.17 Bn | 597.96 Mn | 136.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 4.19 Mn |
| Dec 31, 2024 | 4.51 Mn |
| Sep 30, 2024 | 5.34 Mn |
| Jun 30, 2024 | 2.82 Mn |
| Mar 31, 2024 | 5.31 Mn |
| Dec 31, 2023 | 5.55 Mn |
| Sep 30, 2023 | 5.66 Mn |
| Jun 30, 2023 | 5.78 Mn |
| Mar 31, 2023 | 5.87 Mn |
| Dec 31, 2022 | 3.10 Mn |
| Sep 30, 2022 | 1.72 Mn |
| Jun 30, 2022 | 826,000.00 |
| Mar 31, 2022 | 415,000.00 |
| Dec 31, 2021 | -47,000.00 |
| Sep 30, 2021 | 31,000.00 |
| Jun 30, 2021 | 418,000.00 |
| Mar 31, 2021 | 272,000.00 |
| Dec 31, 2020 | 332,000.00 |
| Sep 30, 2020 | 143,000.00 |
| Jun 30, 2020 | 367,000.00 |